Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Stock Quote

NASDAQTROV
$3.09
NASDAQTROV
Open
$3.13
Change
-$0.02 (-0.64%)
Day's Range
$3.06 - $3.16
52-Week Range
$2.54 - $20.26
Volume
22.6K
Market Cap
$16.2M